In January 2025, psychedelic research saw modest activity, contributing 11 new studies and 183 linked studies. This month’s additions include clinical trial results, real-world implementation studies, and analyses that further our understanding of these innovative treatments.
In December 2024, psychedelic research slowed, adding 14 studies, 130 links, and insights on clinical trials, re-analyses, and global progress.
Links to all psychedelic research published in 2025. From clinical trials and observational studies to reviews and animal studies.
In the November recap, we explore the neuroplasticity mechanisms of psychedelics, their therapeutic applications for mental health conditions like OCD and fibromyalgia, safety considerations, and the significant role of user experiences in therapeutic outcomes.
In October we investigate discontinuation of antidepressants and psychedelic treatments, 2C-B effects, and neurofeedback and psychedelics.
Psychedelic research in September 2024 covered mescaline dosing, meditation, psilocybin for veterans, harmine dosing, and more
The psychedelic research from July and August 2024. Covering LSD follow-up, R vs S-MDMA, and false insights after psychedelics.
Psychedelic research in June 2024 investigated the coupling of psychedelics (and benzos), the role of purging, and ethical guidelines
Psychedelic research in May 2024 investigates awe in ketamine therapy, role of therapy in PAT, touch guidelines, real world impact of psychedelics, and more.
April 2024 psychedelic research explores mechanisms, addresses challenges, compares MDMA to amphetamines, reviews 5-MeO-DMT, and investigates novel therapeutic applications for seizures, personality disorders, and cluster headaches.